Antirheumatic drugs, B cell depletion and critical COVID-19 : correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al
| Errataetall: |
CommentOn: Ann Rheum Dis. 2020 Jun;79(6):837-839. - PMID 32332072 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 81(2022), 11 vom: 15. Nov., Seite e216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Notz, Quirin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 14.10.2022 Date Revised 07.12.2022 published: Print-Electronic CommentOn: Ann Rheum Dis. 2020 Jun;79(6):837-839. - PMID 32332072 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-218778 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314327746 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314327746 | ||
| 003 | DE-627 | ||
| 005 | 20231225152506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-218778 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314327746 | ||
| 035 | |a (NLM)32859609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Notz, Quirin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antirheumatic drugs, B cell depletion and critical COVID-19 |b correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.10.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2020 Jun;79(6):837-839. - PMID 32332072 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a B-lymphocytes | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Meybohm, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Kranke, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Weismann, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Lotz, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Schmalzing, Marc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 81(2022), 11 vom: 15. Nov., Seite e216 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2022 |g number:11 |g day:15 |g month:11 |g pages:e216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-218778 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2022 |e 11 |b 15 |c 11 |h e216 | ||